| Execution period | 1 year |
|---|
BSE filing, NSE: ICICIBANK. Summary written from the filing by ALFA Finder's alert engine.
ICICI Bank Ltd: key numbers
- Share price
- ₹1,377.60
- Market cap
- ₹9,89,105 Cr
- Revenue (annual)
- ₹1,95,218 Cr
- Net profit (annual)
- ₹54,208 Cr
- P/E (TTM)
- 16.8×Sector 19.7×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 34.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ICICI Bank Ltd
All →ICICI Bank Credit Rating
ICRA and CARE reaffirmed ICICI Bank's credit ratings on October 23, 2026, with ICRA withdrawing ratings on matured instruments. The filing discloses no new money raised.
ICICI Bank Employee Stock Options
ICICI Bank reissued 24,096 forfeited shares under its ESUS scheme on 22 Oct 2026. No issue price is disclosed in the filing.
ICICI Bank Other Announcement
ICICI Bank Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
ICICI Bank Management Change
ICICI Bank's Board approved seeking RBI approval for the continuation of Mr. Pradeep Kumar Sinha as Non-executive Part-time Chairperson until February 16, 2029.
ICICI Bank Earnings Call Transcript: Key Takeaways
Strong core operating profit growth of 21.8% YoY driven by robust loan expansion despite moderate NIM compression.
ICICI Bank Investor Presentation: Key Takeaways
ICICI Bank reported strong Q2-2027 performance with PAT up 20.1% YoY to ₹148.43 bn. Growth was driven by robust credit demand and stable asset quality.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.